Close

Anti-ANTXR1 TCR-ABR-β (XW-15) CAR Vector (XS-1122-YF1855)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-ANTXR1 TCR-fused Antigen Binding Receptor (TCR-ABR) CAR is constructed for the engineering of T cells to target Human ANTXR1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv (XW-15) of anti-ANTXR1 antibody linked to TCRβ subunit. The vector product was designed for the discovery and development of cellular therapy against Gastric, breast, colon, and pancreatic tumors. The TCR-ABR can effectively reprogram an intact TCR complex to recognize tumor surface antigens. TCR-ABR-T cells are shown to engage the signaling capacity of the entire TCR complex in an HLA-independent manner.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • ANTXR1
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Gastric, breast, colon, and pancreatic tumors
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-TCRβ
  • Discription of Signaling Cassetes
  • The scFv used to generate CAR-T cells or single domain antibodies can be fused to the extracellular N-termini of TCRα, TCRβ, CD3γ, CD3δ, or CD3ε subunits, resulting in the activation of target-specific TCR-ABR-T cells. TCR-ABR-T cells have been shown to use the entire TCR complex's signaling capacity in an HLA-independent manner.

Target

  • Clone
  • XW-15
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • ANTXR cell adhesion molecule 1
  • Synonyms
  • ATR; GAPO; TEM8
  • Introduction
  • This gene encodes a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. The encoded protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants that encode different protein isoforms have been described.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ANTXR1 TCR-ABR (scFv-TCRβ, XW-15) CAR Plasmid, pCDCAR1 (XS-1122-YF1855). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.